Synergistic Protection against Secondary Pneumococcal Infection by Human Monoclonal Antibodies Targeting Distinct Epitopes

Secondary streptococcal infection following influenza

(2022) Nobuo Okahashi et al.   MICROBIOLOGY AND IMMUNOLOGY

Diverse Mechanisms of Protective Anti-Pneumococcal Antibodies

(2022) Aaron D. Gingerich et al.   Frontiers in Cellular and Infection Microbiology

Sequential targeting of interferon pathways for increased host resistance to bacterial superinfection during influenza

(2021) Tarani Kanta Barman et al.   PLoS Pathogens

Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection

(2021) Jiachen Huang et al.   INFECTION AND IMMUNITY

A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies

(2021) Ahmet Ozdilek et al.   mBio

Pan-ebolavirus protective therapy by two multifunctional human antibodies

(2021) Pavlo Gilchuk et al.   CELL

A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large cps Fragment from an Oral Streptococcus

(2020) Feroze Ganaie et al.   mBio

Influenza Infection Induces Alveolar Macrophage Dysfunction and Thereby Enables Noninvasive Streptococcus pneumoniae to Cause Deadly Pneumonia

(2020) Atul K. Verma et al.   JOURNAL OF IMMUNOLOGY

Antibody recognition of the Pneumovirus fusion protein trimer interface

(2020) Jiachen Huang et al.   PLoS Pathogens

Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe

(2019) C. Bonnave et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion/empyema after the introduction of PCV13 in Germany

(2019) D. Goettler et al.   VACCINE

Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader

(2019) Groves et al.   Genes

The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017

(2019) Shinthuja Wijayasri et al.   PLoS One

Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study

(2019) Laura L. Hammitt et al.   VACCINE

A Capsular Polysaccharide-Specific Antibody Alters Streptococcus pneumoniae Gene Expression during Nasopharyngeal Colonization of Mice

(2018) Christopher R. Doyle et al.   INFECTION AND IMMUNITY

Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms

(2017) Madeleine C. Mankowski et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study

(2017) Aderonke Odutola et al.   VACCINE

Antibodies to PcpA and PhtD protect mice against Streptococcus pneumoniae by a macrophage- and complement-dependent mechanism

(2017) Lucian Visan et al.   Human Vaccines & Immunotherapeutics

Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective

(2016) Lindsay Kim et al.   CLINICAL MICROBIOLOGY REVIEWS

Nonencapsulated Streptococcus pneumoniae : Emergence and Pathogenesis

(2016) Lance E. Keller et al.   mBio

Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies

(2015) Eun Hwa Choi et al.   Clinical and Vaccine Immunology

Influenza Promotes Pneumococcal Growth during Coinfection by Providing Host Sialylated Substrates as a Nutrient Source

(2014) Steven J. Siegel et al.   Cell Host & Microbe

Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study

(2014) Nick J Andrews et al.   LANCET INFECTIOUS DISEASES

Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults

(2014) John D. Grabenstein et al.   VACCINE

Depletion of Alveolar Macrophages during Influenza Infection Facilitates Bacterial Superinfections

(2013) H. E. Ghoneim et al.   JOURNAL OF IMMUNOLOGY

Immune Dysfunction and Bacterial Coinfections following Influenza

(2013) D. W. Metzger et al.   JOURNAL OF IMMUNOLOGY

Bacterial Complications of Respiratory Tract Viral Illness: A Comprehensive Evaluation

(2013) A. R. Falsey et al.   JOURNAL OF INFECTIOUS DISEASES

Kinetics of Coinfection with Influenza A Virus and Streptococcus pneumoniae

(2013) Amber M. Smith et al.   PLoS Pathogens

MHC class I–specific antibody binding to nonhematopoietic cells drives complement activation to induce transfusion-related acute lung injury in mice

(2011) Richard T. Strait et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages

(2010) Kevin Fabrizio et al.   VACCINE

Influenza Virus Infection Decreases Tracheal Mucociliary Velocity and Clearance ofStreptococcus pneumoniae

(2009) Lynnelle A. Pittet et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Human Neutrophils Kill Streptococcus pneumoniae via Serine Proteases

(2009) A. J. Standish et al.   JOURNAL OF IMMUNOLOGY

Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness

(2008) David M. Morens et al.   JOURNAL OF INFECTIOUS DISEASES